CW January 2004
Volume 13Issue Number 1 January 2004 ISSN 10593802 Alemtuzumab Improves Remission Quality in CLLIn patients with chronic lymphocytic leukemia (CLL) who are in remission after chemotherapy, alemtuzumab (Campath-1H) improves the quality of remissions, achieving molecular remissions in some cases, according to clinical trial results presented at the 2003 Annual Meeting of the American Society of Hematology. Alemtuzumab is a humanized monoclonal antibody.
Go to Previous Page Go to Next Page Source & Additional Reading 2003 Annual Meeting of the American Society of Hematology Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
